The subgroup analysis of 27 patients with MPO-ANCA–positive GPA showed that 8 of 10 rituximab recipients and 8 of 17 cyclophosphamide recipients met the primary end point (unweighted RR, 1.73 [95% CI, 0.96-3.11]). Here, MPO is linked to granulomatosis with polyangiitis.